白蛋白结合型紫杉醇治疗晚期恶性肿瘤的疗效与安全性研究  

Efficacy and Safety of Nab-paclitaxel in Advanced Solid Tumor Patients

作　　者：凌扬[1] 徐建忠[1] 杨全良[1] 盛桂凤[1] 周彤[1] 

机构地区：[1]苏州大学附属常州肿瘤医院肿瘤内科,江苏省常州市213000

出　　处：《中国肿瘤临床》2012年第2期107-109,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:观察白蛋白结合型紫杉醇治疗晚期恶性肿瘤的疗效和安全性。方法:25例晚期恶性肿瘤患者接受含白蛋白结合型紫杉醇方案(白蛋白结合型紫杉醇130 mg/m^2,第1天、第8天)每21 d为1周期,至少2个周期后评价疗效。结果:25例患者中总有效率56%(14/25),临床受益率76%(19/25),中位TTP5.6(2.1～11.6)个月。不良反应主要为中性粒细胞减少(12%),外周神经损害(8%)和肌肉酸痛乏力(12%)。结论:白蛋白结合型紫杉醇方案治疗晚期恶性肿瘤疗效确切,安全性良好。Objective： To evaluate the efficacy and the safety of nab-paclitaxel in advanced solid tumor patients. Methods： Twen- ty-five patients with solid tumor received nab-paclitaxel-based （nab-paclitaxel 130 mg/m2dl, 8） regimes every 3 wk. All of the patients were evaluated for efficacy and safety at least after 2 cycles. Results： Of the 25 patients, 14 had partial response whereas 5 had stable disease. The response and clinical benefit rates were 59% and 76%, respectively. The median time to progression was 5.6 months. The predominant toxicities were neutropaenia （12%）, neuropathy （8%）, and muscle pain （12%）. Conclusion： The nab-paclitaxel-based regi- men was effective and tolerable in advanced solid tumor.

关 键 词：白蛋白结合型紫杉醇 晚期实体瘤 疗效 安全性 

分 类 号：R730.5[医药卫生—肿瘤]